Recently, Ocutrx Technologies introduced HemoLucence, a tool for rendering real-time 3D visualisation of tissue, which may be traditionally obscured by blood.
Ocutrx developed the innovative visualisation tool through its R&D division, Genius Labs, leading to a “world-first” innovation. HemoLucence also includes the OR-Bot 3D Surgical Microscope System, which is entering clinical trials in 2025 or 2026.
Michael A. H. Freeman, J.D., CEO/CTO of Ocutrx, added:
The Ocutrx OR-Bot 3D Surgery Microscope’s ability to turn blood clear during surgery is a monumental achievement for the future of surgery, and a new high mark for Ocutrx’s journey towards pioneering innovation in healthcare. Our team at the Ocutrx Genius Labs worked tirelessly with me for two years to develop this remarkable technology that sets a new bar for surgical precision and visualization.
The HemoLucence breakthrough leverages RT3D digital volumetric reconstruction and de-scattering algorithms to create useful visualisations of anatomy constructed under blood. Ocutrx notes that system tests were successfully visualised at an accuracy of roughly three millimetres.
RT3D: Breakthrough in Patient Care?
“The ability to render blood ‘transparent’ now makes the unseen, in the heat of surgical battle, seen, creating another layer of safety and confidence for surgeons that traditional visual aids can’t provide,” explained Dr. Leonel Hunt, MD, Ocutrx Medical Advisor and attending surgeon at Cedars-Sinai Spine Center and Cedars-Sinai Orthopedic Center in Los Angeles.
Hunt also noted that their primary areas of research interest “involve the development of new surgical technologies and innovative surgical and non-surgical treatments for spine-related neck and back pain, and this is an important new one.”
HemoLucence utilises advanced mathematics and physics to analyse how light behaves as it passes through blood-filled areas. The algorithms collect images from various angles, allowing the system to differentiate between light absorbed by blood and light scattered by red blood cells. This process creates detailed 3D renderings of tissue structure and texture.
Dr. Robert Louis, MD, a neurosurgeon and Director of the Skull Base and Pituitary Tumour Program at Hoag Memorial Hospital in Newport Beach, California, said:
The ability to render blood as transparent will provide a level of visualization not previously possible in any field of surgery. No matter the discipline or scale, bleeding is a regular part of any surgery and can create several challenges. This breakthrough helps overcome those challenges and is a significant step forward in making surgery safer and more efficient.
Ocutrx is focused on driving AR/XR and 3D visualisation across various industries in the US and UK. The firm recently acquired Spectrum Advanced Manufacturing Technologies, allowing for this diversification across aerospace, spaceflight, and defence sectors.
The XR/AR market is defined by software and hardware production, allowing for advanced spatial interactions with RT3D tools. Moves such as Ocutrx’s recent updates showcase a move towards further RT3D workplace integration.
Ocutrx currently holds 42 issued patents across more than 35 patent families, over 50 patents in prosecution, and plans to expand its patent portfolio further.
